Literature DB >> 23994159

Insulin suppresses ischemic preconditioning-mediated cardioprotection through Akt-dependent mechanisms.

Tanner M Fullmer1, Shaobo Pei, Yi Zhu, Crystal Sloan, Robert Manzanares, Brandon Henrie, Karla M Pires, James E Cox, E Dale Abel, Sihem Boudina.   

Abstract

It is believed that the diabetic myocardium is refractory to cardioprotection by ischemic preconditioning (IPC) mainly because of impaired insulin signaling to phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB or Akt). However, human as well as animal studies have clearly showed that the hearts of type 2 diabetic humans and animals may exhibit increased signaling through PI3K-Akt but yet are resistant to cardioprotection by IPC or ischemic post-conditioning. Therefore, this study was designed to determine whether activation of insulin signaling prior to IPC is detrimental for cardioprotection and to assess the role of insulin receptors (IRs) and Akt in mediating this effect. Wild-type (WT) hearts, hearts lacking IRs or hearts expressing an active form of Akt (myrAkt1) were perfused ex vivo using a Langendorff preparation and were subjected to IPC (3cycles of 5min ischemia followed by 5min reflow before 30min no flow ischemia and then by 45min reperfusion) in the presence or absence of 1nmol/L insulin. Interestingly, whereas insulin was protective against I/R (30min no flow ischemia and 45min reperfusion), it completely abolished cardioprotection by IPC in WT hearts but not in mice lacking insulin receptors (IRs) in cardiomyocytes (CIRKO) or in all cardiac cells (TIRKO). The suppression of IPC-mediated cardioprotection was mediated through downstream signaling to Akt and Gsk3β. In addition, transgenic induction of Akt in the heart was sufficient to abrogate IPC even when insulin was absent, further confirming the involvement of Akt in insulin's suppression of cardioprotection by IPC. These data provide evidence that excessive insulin signaling to Akt is detrimental for cardioprotection by IPC and could explain the failure of the diabetic myocardium to precondition.
© 2013. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cardioprotection; Insulin; Insulin signaling; Ischemia; Reperfusion

Mesh:

Substances:

Year:  2013        PMID: 23994159      PMCID: PMC3835741          DOI: 10.1016/j.yjmcc.2013.08.005

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  51 in total

1.  GSK-3β at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways.

Authors:  François Vigneron; Pierre Dos Santos; Sandrine Lemoine; Maryline Bonnet; Liliane Tariosse; Thierry Couffinhal; Cécile Duplaà; Béatrice Jaspard-Vinassa
Journal:  Cardiovasc Res       Date:  2011-01-13       Impact factor: 10.787

2.  Duration and type of therapy for diabetes: impact on cardiac risk stratification with stress electrocardiographic-gated SPECT myocardial perfusion imaging.

Authors:  Dimitrios Barmpouletos; Gerasimos Stavens; Alan W Ahlberg; Deborah M Katten; David M O'Sullivan; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2010-10-21       Impact factor: 5.952

3.  Tetrahydrobiopterin analogues with NO-dependent pulmonary vasodilator properties.

Authors:  Suma P Kunuthur; Philip H Milliken; Colin L Gibson; Colin J Suckling; Roger M Wadsworth
Journal:  Eur J Pharmacol       Date:  2010-10-13       Impact factor: 4.432

4.  Pretreatment with insulin before ischaemia reduces infarct size in Langendorff-perfused rat hearts.

Authors:  B N Fuglesteg; C Tiron; A K Jonassen; O D Mjøs; K Ytrehus
Journal:  Acta Physiol (Oxf)       Date:  2009-02       Impact factor: 6.311

5.  The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.

Authors:  Linda G Mellbin; Klas Malmberg; Anna Norhammar; Hans Wedel; Lars Rydén
Journal:  Eur Heart J       Date:  2007-12-21       Impact factor: 29.983

6.  Glycogen synthase kinase-3 inactivation is not required for ischemic preconditioning or postconditioning in the mouse.

Authors:  Yasuhiro Nishino; Ian G Webb; Sean M Davidson; Aminul I Ahmed; James E Clark; Sebastien Jacquet; Ajay M Shah; Tetsuji Miura; Derek M Yellon; Metin Avkiran; Michael S Marber
Journal:  Circ Res       Date:  2008-06-26       Impact factor: 17.367

7.  Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice.

Authors:  Omar Bouhidel; Sandrine Pons; Richard Souktani; Roland Zini; Alain Berdeaux; Bijan Ghaleh
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-08-08       Impact factor: 4.733

8.  Contribution of insulin and Akt1 signaling to endothelial nitric oxide synthase in the regulation of endothelial function and blood pressure.

Authors:  J David Symons; Shawna L McMillin; Christian Riehle; Jason Tanner; Milda Palionyte; Elaine Hillas; Deborah Jones; Robert C Cooksey; Morris J Birnbaum; Donald A McClain; Quan-Jiang Zhang; Derrick Gale; Lloyd J Wilson; E Dale Abel
Journal:  Circ Res       Date:  2009-04-02       Impact factor: 17.367

9.  Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction.

Authors:  Stuart A Cook; Anabel Varela-Carver; Marco Mongillo; Christina Kleinert; Muhammad T Khan; Lucia Leccisotti; Nicola Strickland; Takashi Matsui; Saumya Das; Anthony Rosenzweig; Prakash Punjabi; Paolo G Camici
Journal:  Eur Heart J       Date:  2009-10-01       Impact factor: 29.983

10.  Preconditioning the diabetic human myocardium.

Authors:  Vivek Sivaraman; Derek J Hausenloy; Abigail M Wynne; Derek M Yellon
Journal:  J Cell Mol Med       Date:  2009-06-05       Impact factor: 5.310

View more
  15 in total

Review 1.  Myocardial autophagic energy stress responses--macroautophagy, mitophagy, and glycophagy.

Authors:  Lea M D Delbridge; Kimberley M Mellor; David J R Taylor; Roberta A Gottlieb
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-03-06       Impact factor: 4.733

2.  Syntaxin 1A mediates isoflurane but not hypoxia preconditioning-induced alleviation of hypoxia-reoxygenation injury in rat cardiomyocytes.

Authors:  Meng Liu; Hao Zhang; Qingqing Zhang; Caiguo Huang; Xueyin Shi
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

Review 3.  Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes.

Authors:  Christopher J Nolan; Neil B Ruderman; Steven E Kahn; Oluf Pedersen; Marc Prentki
Journal:  Diabetes       Date:  2015-03       Impact factor: 9.461

Review 4.  Insulin Signaling and Heart Failure.

Authors:  Christian Riehle; E Dale Abel
Journal:  Circ Res       Date:  2016-04-01       Impact factor: 17.367

Review 5.  Molecular mechanisms of diabetic cardiomyopathy.

Authors:  Heiko Bugger; E Dale Abel
Journal:  Diabetologia       Date:  2014-01-30       Impact factor: 10.122

6.  mTOR Mediated Metabolic Rewiring and Ischemic Preconditioning, its Complicated.

Authors:  E Dale Abel
Journal:  Circ Res       Date:  2021-03-05       Impact factor: 17.367

Review 7.  Insulin signaling in the heart.

Authors:  E Dale Abel
Journal:  Am J Physiol Endocrinol Metab       Date:  2021-05-31       Impact factor: 5.900

8.  Acute hyperglycemia abolishes cardioprotection by remote ischemic perconditioning.

Authors:  Tamás Baranyai; Csilla Terézia Nagy; Gábor Koncsos; Zsófia Onódi; Melinda Károlyi-Szabó; András Makkos; Zoltán V Varga; Péter Ferdinandy; Zoltán Giricz
Journal:  Cardiovasc Diabetol       Date:  2015-11-18       Impact factor: 9.951

Review 9.  The role of hexokinase in cardioprotection - mechanism and potential for translation.

Authors:  Andrew P Halestrap; Gonçalo C Pereira; Philippe Pasdois
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

10.  Effect of pioglitazone on the abrogated cardioprotective effect of ischemic preconditioning in hyperlipidemic rat heart.

Authors:  Dhiraj Mittal; Rajeev Taliyan; P L Sharma; Harlokesh Narayan Yadav
Journal:  Indian J Pharmacol       Date:  2016 Jan-Feb       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.